Table 2.
NPs | Lipid | Application | Reference |
---|---|---|---|
Magnetic
Nanoparticle |
PE-based Lipids: DSPE, DOPE, DMPE, DPPE, DSPE-PEGx |
MRI Contrast Agents Drug/Gene Delivery |
29-31, 33, 42, 47, 48, 53 5, 32, 45, 48 |
PC-Based Lipids: DOPC, DPPC, DSPC DLPC |
MRI Contrast Agents Hyperthermia |
53 33, 34 |
|
Cationic Lipids: DOTAP |
MRI Contrast Agents | 42 | |
Quantum Dot |
PE-based Lipids: DSPE, DOPE, DMPE DSPE-PEGx |
Imaging, Diagnostics Drug/Gene Delivery |
3, 70-73, 79, 81, 82 73, 79, 82 |
PC-Based Lipids: DOPC, DPPC, DSPC, MHPC |
Imaging, Diagnostics Drug/Gene Delivery |
3, 70-72, 74, 79 79 |
|
Cationic Lipids: DOTAP |
Imaging, Diagnostics Drug/Gene Delivery |
73, 74, 79 73, 79 |
|
Gold
nanoparticle |
PE-based Lipids: DSPE, DMPE DSPE-PEGx |
Imaging Diagnostics | 92 |
PC-Based Lipids: DOPC, DPPC, DSPC, MHPC |
Imaging, Diagnostics Drug/Gene Delivery |
90-94 88 |
|
Silica
Nanoparticle |
PE-based Lipids: DSPE, DOPE, DMPE DSPE-PEGx |
Drug/Gene Delivery | 116, 117 |
PC-Based Lipids: DOPC, DPPC, DSPC, DMPC, MHPC, POPC |
Imaging, Diagnostics Drug/Gene Delivery |
107, 113, 115 112-121 |
|
Cationic Lipids: DOTAP |
Drug/Gene Delivery | 107, 116, 117, 121 | |
Polymeric
Nanoparticle |
PE-based Lipids: DSPE, DOPE, DMPE DSPE-PEGx |
Drug/Gene Delivery | 128-131 |
PC-Based Lipids: DOPC, DPPC, DSPC, DMPC, DLPC |
Drug/Gene Delivery |
127, 129, 130, 132 134-136 |
|
Cationic Lipids: DPTAP | Drug/Gene Delivery | 127, 132 |